Skip to Main Content
Lantern_Icon_blue
Lantern by Labaton
Link_Arrow
ClientConnect_Icon_blue
Client Connect
Link_Arrow
Labaton Logo
  • The Firm
  • Practices
  • Our Team
  • Cases
  • News & Insights
  • Client Services
  • Careers
Contact Us
Established 1963

Back to Resolved Cases
Practice Area: Securities Litigation
Updated: December 4, 2019

In re Prothena Corporation PLC Securities Litigation

Case Materials

Joint Declaration
Memorandum of Law in Support of Motion for an Award of Attorneys' Fees and Payment of Litigation Expenses
Notice of Motion for an Award of Attorneys' Fees and Payment of Litigation Expenses
Memorandum of Law in Support of Motion for Final Approval of Class Action Settlement and Approval of Plan of Allocation
Notice of Motion for Final Approval of Class Action Settlement and Approval of Plan of Allocation
Preliminary Approval of Class Action Settlement
Notice and Claim Form
Stipulation and Agreement of Settlement
Amended Complaint
Final Order and Judgment
Order Approving Plan of Allocation
Order Awarding Attorneys’ Fees and Expenses

On October 31, 2018, Labaton Keller Sucharow was appointed co-lead counsel in a securities class action lawsuit against Prothena Corporation plc (Prothena), and certain of its senior executives.  The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons or entities that purchased Prothena’s publicly traded common stock between October 15, 2015, and April 20, 2018, inclusive.

On August 26, 2019, the parties executed a Stipulation and Agreement of Settlement for $15.75 million.  Final Judgment was entered on December 4, 2019.

Prothena is a development-stage biotechnology company.  During the class period, Prothena’s principal asset was NEOD001, a drug designed to treat amyloid light chain amyloidosis (“AL amyloidosis”), a rare, progressive, and typically fatal disease, resulting in organ damage and failure.

The Amended Complaint alleges that defendants misleadingly cited the results of Prothena’s ongoing Phase 1/2 clinical study of NEOD001 as evidence that the drug was effective and provided a strong basis for late-stage Phase 2b and Phase 3 studies of NEOD001.  In truth, NEOD001 was not an effective treatment for AL amyloidosis and did not provide an adequate basis for the late-stage Phase 2b and Phase 3 studies.  When the truth regarding NEOD001’s prospects was finally revealed, the price of the Company’s stock declined by over 69 percent.

The case is In re Prothena Corporation PLC Securities Litigation, No. 18-cv-06425 (S.D.N.Y.).  Lead plaintiffs are Granite Point Capital, Granite Point Capital Master Fund, LP, Granite Point Capital Panacea Heatlhcare, Grant Point Scorpion Focused Ideas Fund (collectively, Granite Point) and Simon James.  Labaton Keller Sucharow represents Granite Point.

Settlement Hearing

A Settlement Hearing was held December 2, 2019, before the Honorable Andrew L. Carter, Jr., 11:30 a.m. in Courtroom 1306 of the United States District Court for the Southern District of New York, Thurgood Marshall United States Courthouse, 40 Foley Square, New York, NY 10007.

If you have questions about the Settlement, please contact Labaton Keller Sucharow at settlementquestions@labaton.com or 1-888-219-6877, or contact the Claims Administrator, Strategic Claims Services at (877) 310-6376.

logo

Our Locations

New York

140 Broadway
New York, NY 10005
Tel: +1 212.907.0700

Delaware

222 Delaware Avenue, Suite 1510
Wilmington, DE 19801
Tel: +1 302.573.2540

London

1 King William Street
London, EC4N 7AF United Kingdom
Tel: +44 20 3582 0981

Washington, D.C.

1050 Connecticut Avenue NW, Suite 500
Washington, D.C. 20036
Tel: +1 202.772.1881

Useful Links

  • Practices
  • Cases
  • News & Insights
  • Client Services
  • Contact

The Firm

  • Our Team
  • Our Story
  • Awards & Accolades
  • Offices
  • Social Commitment
  • Careers for Attorneys
  • Careers for Business Professionals
  • Attorney Development

Stay Connected

fbfb
Facebook
Xx
Twitter / X
inin
LinkedIn
Footer_Graphic
© Labaton Keller Sucharow LLP All Rights Reserved 2026
Attorney Advertising DisclaimerPrivacy PolicyCookie PolicyCalifornia Privacy Policy and Notice of Collection of Personal InformationTransparency in Coverage Rule